LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ:
CRIS), a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer, today
announced that it will host a virtual KOL event to discuss progress
to date for CA-4948, a first-in-class IRAK4 kinase inhibitor,
including updated data presented at the European Hematology
Association 2021 Virtual Congress from the Phase 1/2 study of
CA-4948 in patients with AML or high-risk MDS. The event will be
held on Friday, June 11, 2021 at
8:00 am ET.
The event will be led by James
Dentzer, President and CEO, and will include a presentation
by Dr. Guillermo Garcia-Manero,
M.D., Chief of the Section of Myelodysplastic Syndromes within the
Department of Leukemia at the University of
Texas MD Anderson Cancer Center. The speakers and additional
members of Curis leadership will be available to answer questions
at the end of the event.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website at www.curis.com. A replay of the webcast will be
available on the Curis website for approximately 90 days following
the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1/2 trial in patients with
non-Hodgkin's lymphoma both as a monotherapy and in combination the
with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a
Phase 1/2 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes, for which it has received Orphan Drug
Designation from the U.S. Food and Drug Administration. In
addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody,
which is currently undergoing testing in a Phase 1 trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis' website at www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-to-host-virtual-event-to-discuss-updated-clinical-data-for-ca-4948-in-amlmds-presented-at-eha-301305863.html
SOURCE Curis, Inc.